Found 6 matching trials
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) PHASE2 This single-arm, open-label phase II study aim to evaluate the efficacy and...
Show More Location
Chinese Academy of Medical Science and Blood Disease Hospital
Learn More & Join Trial
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers PHASE1 This is an open label, Phase 1/2, first-in-human, multiple ascending dose, ...
Show More Location
Valkyrie Clinical Trials
Learn More & Join Trial
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma PHASE1 Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment c...
Show More Location
Western Regional Medical Center - CTCA
Learn More & Join Trial
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia PHASE4 This prospective, single-arm, multicenter, exploratory study will enroll 38...
Show More Location
Ethics Committee of Hematology Hospital, Chinese Academy of Medical Sciences
Learn More & Join Trial
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma PHASE1 This is a Phase I open-label, multicenter study designed to evaluate the sa...
Show More Location
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center
Learn More & Join Trial
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) PHASE2 This randomized, open-label study aim to compare the efficacy and safety of...
Show More Location
Chinese Academy of Medical Science and Blood Disease Hospital
Learn More & Join Trial